Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
Resonance Health (ASX:RHT), a medical imaging and clinical services company, is transitioning into a profitable business, according to SG Hiscock. In July 2026, SG Hiscock said Resonance Health continued its transition from a small medical imaging software business into a profitable, diversified healthcare services company. Resonance Health operates in the Healthcare sector within the Healthcare Equipment and Supplies industry, and Thesis Tracker has captured 1 comment from 1 fund manager, SG Hiscock & Company. Headquartered in Perth, Resonance Health develops and commercialises quantitative image analysis technologies, including FerriScan for measuring liver iron concentration using MRI, used by clinicians and pharmaceutical companies worldwide, and has expanded into clinical trial services and specialist healthcare businesses through acquisitions such as TrialsWest.
Company figures as of 15 Oct 2026. For information only.
Fund managers including SG Hiscock & Company have invested in Resonance Health Ltd (ASX:RHT).
SG Hiscock highlights Resonance's transition into a profitable, diversified healthcare services company.
The available commentary does not detail specific risks, though Resonance must integrate acquisitions and sustain growth.
Resonance Health Ltd. is a healthcare company that develops and commercializes technologies and services for quantitative analysis of radiological images in a regulated, quality-controlled environment. Headquartered in Burswood, Australia, and founded by Santino Di-Giacomo in 1987, the company operates through three segments: Services, Corporate, and Research and Development. Resonance Health focuses on image-analysis technology supporting diagnostic and research applications, combining clinical-grade quality standards with ongoing R&D to advance radiological imaging solutions for healthcare providers.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.